
The US-based pharmaceutical giant Bristol Myers Squibb has seen progress in the year's third quarter, increasing product revenue for several of its drugs, it reported in a press release on Wednesday.
The sales of cancer drugs Revlimid and Opdivo increased by a respective 11 percent and 7 percent, reaching USD 3.3bn and USD 1.9bn in the months July, August and September.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app